CTLA4-Ig interferes and downregulates the proinflammatory activities of rheumatoid synovial macrophages in monoculture

  • R. Brizzolara Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
  • S. Soldano Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
  • P. Montagna Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
  • A. Sulli Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
  • B. Seriolo Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genov, Italy.
  • B. Villaggio Unità di Clinica Nefrologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
  • P.F. Triolo Unità di Artrite Reumatoide, Dipartimento di Chirurgia Ortopedica, Ospedale CTO, Torino, Italy.
  • P. Clerico Unità di Artrite Reumatoide, Dipartimento di Chirurgia Ortopedica, Ospedale CTO, Torino, Italy.
  • L. Felli Dipartimento di Ortopedia, Università di Genova, Italy.
  • L. Molfetta Unità Ortopedica, Ospedale San Martino, Genova, Italy.
  • M. Cutolo | vmcutolo@unige.it Laboratorio di Ricerca e Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.

Abstract

Objective: CTLA4-Ig, a biologic agent employed in rheumatoid arthritis (RA) treatment, downregulates the immune response and exerts anti-inflammatory effects acting on different cells including dendritic/T cells interaction and directly on osteoclasts. We investigated the anti-inflammatory effects of CTLA4-Ig in primary monocultures of RA synovial macrophages (SM). Methods SM were obtained, from 8 RA patients (7 F, 1 M; DAS28>5.2) who underwent therapeutic arthroscopic synoviectomy and were cultured in the absence and in the presence of CTLA4-Ig at the concentration of [500 μg/ml], the most reliable dose related to the previous pharmacological clinical and experimental experiences. Inflammatory cytokine (IL-6, TNFalpha, IL-1beta) expression was evaluated by immunocytochemistry (ICC with relative image analysis), western blot (WB), and quantitative real-time polymerase chain reaction (qRT-PCR). Results: ICC analysis revealed that CTLA4-Ig treatment significantly downregulated cytokine expression (p<0.001 for IL-6, TNFalpha and IL-1beta) when compared to untreated RA SM. WB and qRT-PCR confirmed partially the data. Conclusions: CTLA4-Ig was found to exert a direct and significant anti-inflammatory effect on primary monocultures of RA SM, suggesting a therapeutic power in different phases of the disease activity.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Keywords:
rheumatoid arthritis, synovial macrophages, costimolatory molecules, CTLA4-Ig
Statistics
  • Abstract views: 924

  • PDF: 606
How to Cite
Brizzolara, R., Soldano, S., Montagna, P., Sulli, A., Seriolo, B., Villaggio, B., Triolo, P., Clerico, P., Felli, L., Molfetta, L., & Cutolo, M. (1). CTLA4-Ig interferes and downregulates the proinflammatory activities of rheumatoid synovial macrophages in monoculture. Reumatismo, 63(2), 80-85. https://doi.org/10.4081/reumatismo.2011.80